Prospective Students | Students | Faculty | Staff | Patients | Visitors | Alumni
 
 
Faculty Profile

Bryan R. Haugen, M.D., Mary Rossick Kern and Jerome H. Kern Endowed Chair in Endocrine Neoplasms Research, Professor of Medicine and Pathology, Division Head, Endocrinology, Metabolism & Diabetes

Since finishing training at the University of Colorado Health Sciences Center in 1993, Dr. Haugen has been interested in the molecular mechanisms governing thyrotrope function and thyroid neoplasms. He has been studying the cell-specific expression and regulation of TSH including regulation by thyroid hormone and retinoids as well as their respective nuclear receptors. More recently, Dr. Haugen has been studying potential mechanisms involved in thyroid neoplasia and cancer, including the roles of retinoic acid receptors (RAR, RXR), retinoids, peroxisome proliferator activated receptors (PPAR) and thiazolidenediones. He has also been involved in novel proteomic analyses of the thyroid gland and thyroid tumors. Clinically, Dr. Haugen is interested in thyroid and pituitary disorders, particularly novel diagnoses for thyroid neoplasms and therapies for thyroid cancer.

Selected Publications

  • Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer, Duncan MW and Haugen BR. Quantitative and Qualitative Differences in Protein Expression Between Papillary Thyroid Carcinoma and Normal Thyroid Tissue. Molecular Carcinogenesis, 45:613-26, 2006. PUBMED

  • Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI and Tuttle RM. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 16:109-142, 2006. PUBMED

  • Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong A, Kreinest P, Williams SF, Haugen BR, Klopper JP and Smallridge RC. Novel High affinity PPARγ agonist alone and in combination with Taxol inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene, 13;25(16):2304-17, 2006. PUBMED

  • Sharma V, Hays WR, Wood WM, Pugazhenthi U, St. Germain DL, Bianco AC, Krezel W, Chambon P and Haugen BR. Effects of Retinoids on Thyrotrope Function and the Hypothalamic-Pituitary-Thyroid Axis. Endocrinology 147:1438-1551, 2006. PUBMED

  • Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, and Haugen BR. RXRg and PPARg expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Molecular Cancer Therapeutics 3:1011-1020, 2004. PUBMED

  • Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said S, and Haugen BR. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Path 122:524-31, 2004. Haugen BR, Jensen DR, Sharma V, Pulawa LK, Krezel W, Chambon P, and Eckel RH. RXRg deficient mice have increased skeletal muscle lipoprotein lipase activity and less weight gain when fed a high-fat diet. Endocrinology 145:3679-85, 2004. PUBMED

  • Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, and Sharma V. Retinoic acid and retinoid X receptors are differentially expressed expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to natural and synthetic retinoids. J Clin Endo Metab 89:272-280, 2004. PUBMED

  • McDermott NS, Gordon DF, Kramer CA, Liu Q, Linney E, Wood WM, and Haugen BR. Isolation and functional analysis of the mouse RXRg1 gene promoter in anterior pituitary cells. J Biol Chem. 277:36839-44, 2002. PUBMED